Chinese Biotechs Raise $743m In Three March IPOs
RemeGen touched down in Shanghai to score a dual listing on top of a 2020 initial public offering in Hong Kong. Meanwhile, domestic HPV vaccine maker Recbio and small molecule-focused Shouyao made their debuts on the Hong Kong and Shanghai markets respectively.
You may also be interested in...
RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.
After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.